3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
CNS
1
Conditions
Ovarian Neoplasms
8
Uterine Cervical Neoplasms
2
Peritoneal Neoplasms
2
Fallopian Tube Neoplasms
2
Recurrence
1
Ovarian Diseases
1
Neoplasms by Site
1
Neoplasms
1
Endometrial Neoplasms
1
Endometrial Adenocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma
1
Interventions
Carboplatin
19
Paclitaxel
17
Cisplatin
9
Cyclophosphamide
8
Gemcitabine
7
Bevacizumab
6
Topotecan
5
pembrolizumab
4
olaparib
4
liposomal doxorubicin
4
durvalumab
4
Letrozole
4
Interleukin-2
4
Drug Therapy
4
Doxorubicin
4
Albumin-Bound Paclitaxel
4
rucaparib
3
fludarabine
3
chiauranib
3
cemiplimab
3
camrelizumab
3
Therapeutics
3
Itraconazole
3
Injections
3
Hyperthermic Intraperitoneal Chemotherapy
3
Everolimus
3
pazopanib
2
iniparib
2
eprenetapopt
2
avelumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
nintedanib
×
Gynecologic
×
Clear all
NCT01610869
2019-05-29
METRO-BIBF
University College, London
Phase 2
Completed
117 enrolled